Arno Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes innovative products for the treatment of cancer patients.

Arno's lead compound is AR-67, a novel, third-generation camptothecin analogue in Phase I studies in patients with advanced solid tumors. Arno is also developing two pre-clinical compounds. AR-12 is a potential first-in-class, orally available PI3-k/Akt inhibitor undergoing IND-enabling studies. AR-42 is an orally available, targeted inhibitor of the Pan-DAC and Akt pathways also undergoing IND-enabling studies. Arno is actively pursuing additional compounds to expand its portfolio.